It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Vascular endothelial growth factor-A (VEGF) physiologically regulates both angiogenesis and osteogenesis, but its application in bone tissue engineering led to contradictory outcomes. A poorly understood aspect is how VEGF dose impacts the coordination between these two processes. Taking advantage of a unique and highly tunable platform, here we dissected the effects of VEGF dose over a 1,000-fold range in the context of tissue-engineered osteogenic grafts. We found that osteo-angiogenic coupling is exquisitely dependent on VEGF dose and that only a tightly defined dose range could stimulate both vascular invasion and osteogenic commitment of progenitors, with significant improvement in bone formation. Further, VEGF dose regulated Notch1 activation and the induction of a specific pro-osteogenic endothelial phenotype, independently of the promotion of vascular invasion. Therefore, in a therapeutic perspective, fine-tuning of VEGF dose in the signaling microenvironment is key to ensure physiological coupling of accelerated vascular invasion and improved bone formation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Basel University Hospital and University of Basel, Regenerative Angiogenesis Laboratory, Department of Biomedicine, Basel, Switzerland (GRID:grid.410567.1)
2 Basel University Hospital and University of Basel, Regenerative Angiogenesis Laboratory, Department of Biomedicine, Basel, Switzerland (GRID:grid.410567.1); Basel University Hospital, Department of Plastic, Reconstructive, Aesthetic and Hand Surgery, Basel, Switzerland (GRID:grid.410567.1)
3 University of Chicago, Pritzker School of Molecular Engineering, Chicago, USA (GRID:grid.170205.1) (ISNI:0000 0004 1936 7822); Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Department of General and Visceral Surgery, Freiburg, Germany (GRID:grid.5963.9)
4 University of Chicago, Pritzker School of Molecular Engineering, Chicago, USA (GRID:grid.170205.1) (ISNI:0000 0004 1936 7822)